CINT vs CABA Comparison

CI&T Inc operates as a partner in tech-integrated business solutions, helping organizations address complex challenges by integrating business approach, technology, and artificial intelligence into a single, coherent operating model. It is mainly engaged in the development of customizable software through the implementation of software solutions, including machine learning, artificial intelligence, data analytics, cloud migration and mobility technologies. The company provides technology services to various industry verticals, including Financial Services, Consumer Goods, Technology and Communications, Retail and Industrial Goods, Life Sciences, among others. The majority of the revenue is derived from providing technology services. Geographically, maximum revenue is derived from Brazil.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.